211 related articles for article (PubMed ID: 8102183)
1. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.
Ratliff TL; Ritchey JK; Yuan JJ; Andriole GL; Catalona WJ
J Urol; 1993 Sep; 150(3):1018-23. PubMed ID: 8102183
[TBL] [Abstract][Full Text] [Related]
2. Role of the immune response in BCG for bladder cancer.
Ratliff TL
Eur Urol; 1992; 21 Suppl 2():17-21. PubMed ID: 1396942
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotypic characterization of the bladder mucosa infiltrating lymphocytes after intravesical BCG treatment for superficial bladder carcinoma.
Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Annoscia S; Lozzi C; Betta PG
Eur Urol; 1992; 21(4):304-8. PubMed ID: 1459153
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
5. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.
Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H
PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942
[TBL] [Abstract][Full Text] [Related]
6. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette-Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway.
Mao MH; Huang HB; Zhang XL; Li K; Liu YL; Wang P
Biomed Pharmacother; 2018 Nov; 107():1093-1103. PubMed ID: 30257321
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
[TBL] [Abstract][Full Text] [Related]
8. Analysis of local T lymphocyte subsets upon stimulation with intravesical BCG: a model to study tuberculosis immunity.
Ponticiello A; Perna F; Maione S; Stradolini M; Testa G; Terrazzano G; Ruggiero G; Malerba M; Sanduzzi A
Respir Med; 2004 Jun; 98(6):509-14. PubMed ID: 15191035
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.
Nadler R; Luo Y; Zhao W; Ritchey JK; Austin JC; Cohen MB; O'Donnell MA; Ratliff TL
Clin Exp Immunol; 2003 Feb; 131(2):206-16. PubMed ID: 12562379
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
11. Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer.
Chin JL; Kadhim SA; Batislam E; Karlik SJ; Garcia BM; Nickel JC; Morales A
J Urol; 1996 Sep; 156(3):1189-93. PubMed ID: 8709344
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer.
Gan YH; Mahendran R; James K; Lawrencia C; Esuvaranathan K
Clin Immunol; 1999 Feb; 90(2):230-7. PubMed ID: 10080835
[TBL] [Abstract][Full Text] [Related]
13. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro.
Thanhäuser A; Böhle A; Flad HD; Ernst M; Mattern T; Ulmer AJ
Cancer Immunol Immunother; 1993 Jul; 37(2):105-11. PubMed ID: 8319241
[TBL] [Abstract][Full Text] [Related]
14. Intravesical BCG Induces CD4
Kates M; Nirschl T; Sopko NA; Matsui H; Kochel CM; Reis LO; Netto GJ; Hoque MO; Hahn NM; McConkey DJ; Baras AS; Drake CG; Bivalacqua TJ
Cancer Immunol Res; 2017 Jul; 5(7):594-603. PubMed ID: 28588015
[TBL] [Abstract][Full Text] [Related]
15. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity.
Ratliff TL; Gillen D; Catalona WJ
J Urol; 1987 Jan; 137(1):155-8. PubMed ID: 3491909
[TBL] [Abstract][Full Text] [Related]
16. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
Front Immunol; 2020; 11():615091. PubMed ID: 33584702
[TBL] [Abstract][Full Text] [Related]
17. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
18. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
19. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer.
Gan YH; Zhang Y; Khoo HE; Esuvaranathan K
Eur J Cancer; 1999 Jul; 35(7):1123-9. PubMed ID: 10533458
[TBL] [Abstract][Full Text] [Related]
20. [Intravesical instillation of BCG for the bladder cancer: relationship between effect and immune cells in peripheral blood and bladder wall].
Chen LZ
Zhonghua Wai Ke Za Zhi; 1993 Jun; 31(6):336-8. PubMed ID: 8313752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
